Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Camonsertib.

Ezra Y Rosen Timothy Anthony Yap Elizabeth K Lee Martin Højgaard Niharika B Mettu Stéphanie Lheureux Benedito Arruda Carneiro Ruth Plummer Adrian J Fretland Danielle Ulanet Yi Xu Robin McDougall Maria Koehler Elisa Fontana

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The prediction of future hemoglobin decrease, after a week of treatment, may enable a personalized, early dose modification to prevent development of clinically significant anemia and resulting unscheduled dose holds or transfusions.

Keyphrases

chronic kidney disease
iron deficiency
dna damage
dna repair
current status
clinical trial
randomized controlled trial
dna damage response
red blood cell
combination therapy
replacement therapy
smoking cessation
double blind